Lynn Kirkpatrick - Concepedia

Author

Lynn Kirkpatrick

University of Arizona

Also Known As

L Kirkpatrick, L. Kirkpatrick, Lynn Kirkpatrick, R. Jones

Publications

Citations

H-Index

Concepts

All Affiliations

University of Arizona The University of Texas MD Anderson Cancer Center University of Pittsburgh Translational Genomics Research Institute Sanford Burnham Prebys Medical Discovery Institute

About

Lynn Kirkpatrick is an author at University of Arizona specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	931
2	Education	1	1	11
3	Natural Sciences	1	1	78
4	Social Sciences	1	1	11
5	Biochemistry	1	1	78

Lynn Kirkpatrick

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Nathan T. Ihle, Ryan Williams, Sherry Chow, Molecular Cancer Therapeutics	2004	311
Hypoxia inducible factor-1α as a cancer drug target Garth Powis, Lynn Kirkpatrick Molecular Cancer Therapeutics	2004	310
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, PubMed Hypoxia-induced Hif-1alpha LevelsAntitumor ActivityChemoprevention StrategyImmunologyCell Death	2004	281
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, Molecular Cancer Therapeutics Hypoxia-induced Hif-1α LevelsAntitumor ActivityCell DeathPharmacotherapyCancer Biology	2004	242
Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-478 Bénédicte F. Jordan, Matthew Runquist, Natarajan Raghunand, Neoplasia	2005	128
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination Ramesh K. Ramanathan, James L. Abbruzzese, Tomislav Dragovich, Cancer Chemotherapy and Pharmacology Advanced CancerOncologyPancreatic CancerMedicinePathology	2010	115
Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice Jörg J. Jacoby, Baruch Erez, Maria Korshunova, Journal of Thoracic Oncology Tumor BiologyLung InflammationMedicineLung AdenocarcinomaImmunology	2010	81
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin Peter Wipf, Daniel J. Minion, Robert J. Halter, Organic & Biomolecular Chemistry Bioorganic ChemistryPharmacotherapyHeterocycle ChemistryChemical BiologyPharmaceutical Chemistry	2004	78
In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316 Emmanuelle J. Meuillet, Nathan T. Ihle, Amanda F. Baker, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics Antitumor ActivityApoptosisCell DeathPharmacotherapyGene Expression Profiling	2004	52
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy Ramesh K. Ramanathan, Joe Stephenson, Glen J. Weiss, Investigational New Drugs 72-Hour InfusionOncologyAdvanced CancersMedicinePharmacotherapy	2011	40

Page 1